Literature DB >> 1792422

Pulmonary hemodynamics in chronic obstructive pulmonary disease of the emphysematous type.

M Oswald-Mammosser1, M Apprill, P Bachez, M Ehrhart, E Weitzenblum.   

Abstract

Pulmonary hemodynamics have been extensively investigated in patients with chronic bronchitis or in 'mixed' patients (chronic bronchitis + emphysema) but rarely in patients with markedly predominant emphysema. We have investigated a large series (n = 151) of such patients, emphysema having been assessed on radiological, clinical and functional grounds. The mean age was 58 +/- 10 years; vital capacity (VC, % of predicted) = 81 +/- 19; forced expiratory volume in 1 s (FEV1) = 1,198 +/- 589 ml; FEV1/VC = 38 +/- 12%; PaO2 = 72 +/- 11 mm Hg; PaCO2 = 37.5 mm Hg. Pulmonary hypertension (PH), defined by a resting pulmonary artery pressure (PAP) of greater than or equal to 20 mm Hg, was present in only 31 of 151 patients. During steady-state exercise (40 W or less) an abnormally high PAP (greater than or equal to 30 mm Hg) was observed in 99 of 151 patients. Resting and exercising PAP were poorly correlated with resting PaO2 and PaCO2, but were better correlated with the amplitude of the respiratory pressure swings, FEV1, the transfer factor and exercising PaO2. Patients with PH (n = 31) showed significantly more obstruction and pulmonary distension than the remainder, but they did not differ from the non-PH patients with regard to resting PaO2. It is concluded that: (1) resting PH is not the rule in diffuse emphysema but exercising hypertension is frequent (2 of 3 patients), and (2) hypoxemia is not a determining factor of hemodynamic abnormalities in emphysema.

Entities:  

Mesh:

Year:  1991        PMID: 1792422     DOI: 10.1159/000195950

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  19 in total

Review 1.  Pulmonary hypertension in chronic obstructive pulmonary disease and emphysema patients: prevalence, therapeutic options and pulmonary circulatory effects of lung volume reduction surgery.

Authors:  Isabelle Opitz; Silvia Ulrich
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

2.  Pulmonary hypertension in a stable community-based COPD population.

Authors:  Vadim Fayngersh; Fotios Drakopanagiotakis; F Dennis McCool; James R Klinger
Journal:  Lung       Date:  2011-08-04       Impact factor: 2.584

Review 3.  COPD exacerbations . 3: Pathophysiology.

Authors:  D E O'Donnell; C M Parker
Journal:  Thorax       Date:  2006-04       Impact factor: 9.139

4.  Assessment of RV Function in Patients of (COPD).

Authors:  Maumita Das; Sumit Roy Tapadar; Anil Baran Singha Mahapatra; Shankar Paul Chowdhury; Subrata Basu
Journal:  J Clin Diagn Res       Date:  2014-03-15

5.  Initial risk assessment for pulmonary hypertension in patients with COPD.

Authors:  Eric J Gartman; Michael Blundin; James R Klinger; Joe Yammine; Mary B Roberts; F Dennis McCool
Journal:  Lung       Date:  2011-11-18       Impact factor: 2.584

Review 6.  State of the Art Review of the Right Ventricle in COPD Patients: It is Time to Look Closer.

Authors:  Daniela Graner Schuwartz Tannus-Silva; Marcelo Fouad Rabahi
Journal:  Lung       Date:  2016-12-03       Impact factor: 2.584

Review 7.  Pulmonary hypertension and chronic cor pulmonale in COPD.

Authors:  Adil Shujaat; Ruth Minkin; Edward Eden
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

Review 8.  Update on pulmonary hypertension complicating chronic obstructive pulmonary disease.

Authors:  Soma Jyothula; Zeenat Safdar
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-24

Review 9.  Hyperinflation and its management in COPD.

Authors:  Luis Puente-Maestu; William W Stringer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

10.  Frequency of pulmonary hypertension in patients with COPD due to biomass smoke and tobacco smoke.

Authors:  Bunyamin Sertogullarindan; Hasan Ali Gumrukcuoglu; Cengizhan Sezgi; Mehmet Ata Akil
Journal:  Int J Med Sci       Date:  2012-07-21       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.